I'm suggesting that blarcamesine works with increasing effect to Week 4, after which it maintains its level of efficacy. It doesn't stop working, it's just that there's a limit to how much good it can do, and that it takes four weeks to reach that limit, which is then maintained -- i.e., the Rett patients keep their clinical improvements from the drug, but don't really keep getting better and better after that.
I also suggest that the remainder of the reported beneficial effect after Week 4 in the dosed arm is a false signal due to the placebo effect in the EXCELLENCE trial. This hypothesis is supported by the identical reported improvements in both arms of the study after Week 4.